Not exact matches
The researchers studied two types
of cells called
effector T cells, which activate the
immune system to defend our body against different pathogens, and regulatory T cells, which help control the
immune system and prevent it from attacking healthy parts
of its environment.
However, it is this small proportion
of virus that hides in the
effector memory T - cells and stops the
immune system from fully destroying the virus and eliminating it from the body.
In many cases the damage is caused by a particular group
of immune cells called
effector memory T - cells.
This «friendly fire» goes unchecked due to the failing
of another type
of immune cell: called the T - reg, which controls T -
effector cells, shutting them down when they are not needed.
Removing one
immune effector element only reveals the presence
of an ancillary pathway for allograft rejection.
Our experts in mucosal vaccine delivery have established in vitro and in vivo models to assess the activity
of adjuvants and vaccine formulations on innate and adaptive
immune cells, as well their capacity to stimulate different
effector mechanisms
of clearance.
The HZI will develop a vaccination protocol for mucosal administration based on three novel strategies: (i) development and optimization
of a vaccination protocol in which parenterally - primed T and B cells are subsequently pulled into the mucosa by the local delivery
of the cognate antigen to the requested
effector site, (ii) testing the co-administration
of antigens with novel mucosal adjuvants using different mucosal immunisation routes and schedules, and (iii) testing various nanoparticles co-administered with different immunomodulators for their ability to generate both systemic and mucosal
immune responses following transcutaneous / trans - follicular vaccination.
Therefore, in both mice and non-human primates, HO - 1 inducers delivered locally inhibited
effector T - cells in an antigen - specific manner, paving the way for repositioning these drugs for the treatment
of immune - mediated diseases.
Apoptosis has been implicated as a T cell - dependent
immune effector mechanism in various forms
of organ graft rejection (29 — 31).
Of special interest were ICOS, whose «role in effector T cell responses and anti-tumor immune responses is now well established,» and CD40, which is «important for the maturation of antigen - presenting cells and for enabling T cell co-stimulation.&raqu
Of special interest were ICOS, whose «role in
effector T cell responses and anti-tumor
immune responses is now well established,» and CD40, which is «important for the maturation
of antigen - presenting cells and for enabling T cell co-stimulation.&raqu
of antigen - presenting cells and for enabling T cell co-stimulation.»
When considering the anatomy
of the mucosal
immune system, sites can be defined as either inductive or
effector sites.
Binding
of adenosine to the A2A receptor on
immune cells blocks the activation and
effector functions
of anti-tumor
immune cells and promotes a regulatory,
immune - suppressive phenotype.
Identify the mechanisms
of autoreactive T
effector and T regulatory expansion in man that can be harnessed to maintain or re-instate self -
immune tolerance.
She is registred to the National Order
of Biologists in the province
of Palermo; collaboration in research project from 2012 to 2015 at the Department
of Biopathology and Biotechnology, University
of Palermo, focusing the study on the identification
of molecules capable to modulate intracellular metabolic pathways for the prevention and treatment
of infectious, tumor and degenerative disease, in collaboration with Prof. Angela Santoni, University
of Rome; collaboration in research project in 2011 at the hospital «Villa Sofia Cervello»
of Palermo to study methods can cure the genetic defect that causes thalassemia through genetic engineering; she studies different mechanisms
of the differentiation and the activation
of human gammadelta T cells as
effector cells
of the
immune response against cancer and infectious diseases; she investigates about the identification and development
of biomarkers
of resistance and susceptibility to Mycobacterium tuberculosis infection; Valentina Orlando has published 13 papers in peer reviewed journals and 3 comunications at national and international congress.
Tryptophan depletion results in the inhibition
of effector T cells and kynurenine accumulation results in the expansion
of immune - suppressant regulatory T cells.
The adenosine A ₂ ₐ receptor is the main adenosine receptor expressed on
immune cell subsets including T - cells, NK cells and dendritic cells and binding
of adenosine to the A ₂ ₐ receptor on
immune cells blocks the activation and
effector functions
of anti-tumor
immune cells and promotes a regulatory,
immune - suppressive phenotype.
Although antimicrobial peptides are not the only functional class to be overrepresented among short, secreted proteins encoded by members
of multi-gene families, the prevalence
of these properties among induced genes strongly suggests the possibly that at least some
of these genes encode novel
immune effectors.
Even though we can not definitively assign these genes an
immune effector role, it is apparent that defensin - like peptides have an unusual diversity in Nasonia, representing 18/34 (52.9 %) homology - annotated AMPs and 6/14 (42.9 %)
of putative novel AMPs.
While it is not straightforward to directly compare the
immune repertoire reported here with previous reports that have used different underlying gene models [15], [34], we do note that our inference about the number and identity
of signaling components is consistent with previous annotations [15], [34], while our inference about recognition and
effectors tends to reflect greater, albeit still relatively minor, differences.
Identifying any Hymenoptera - specific
immune pathways or
effectors that may exist is also
of key importance for understanding the biology
of host - pathogen interactions that may be relevant for such challenges as colony collapse disorder [42]--[44].
The innate
immune system is particularly amenable to characterization with expression - based methodology such as RNA - seq, as one
of the key biological consequences
of pathogenic infections is the rapid induction
of several classes
of effector proteins, along with up - regulation
of a number
of other pathway components.
Therefore the group studies with sophisticated imaging technology in vitro and ex vivo: i) the molecular mechanism driving the migration
of HIV through the intestinal epithelial barrier; ii) the cellular targets in the mucosa, in specific macrophages and DCs, to identify the possible pathways to invade the tissue and disseminate to other organs; iii) the involvement
of DCs and their functional properties in mediating adaptive
immune responses at mucosal level; and iv) the role
of antibodies with different
effector functions in changing the pathways
of the virus.
5/24/2007 How Plague - Causing Bacteria Disarm Host Defense
Effector proteins are the bad guys that help bacterial pathogens do their job
of infecting the host by crippling the body's
immune system.
Priority will be given to studies that evaluate combinations
of agents that induce
immune deviation and / or regulation, produce
effector cell depletion or exhaustion, to achieve durable clinical remission
of disease.
Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the
immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology
of drugs (kinase inhibitors) in the indication oncology, biology
of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast cells as
effector cells in allergic inflammation: characterization
of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation
of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast cells, the allergic
effector unit, mast cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role
of voltage-gated calcium channels
Because the same pool
of naïve T cells can differentiate into inflammatory
effector T cells or inhibitory Tregs, generation
of immune responses requires promoting the differentiation
of inflammatory T cells while reciprocally inhibiting the formation
of Tregs.
Background: Interferon inducible transmembrane (IFITM) proteins are
effectors of the
immune system widely characterized for their role in restricting infection by diverse enveloped and non-enveloped viruses.
Work on NLRP3, IL - 1beta and metabolism formed part
of the renaissance
of interest in immunometabolism, which in this context means intracellular metabolic changes occurring in immunity that are governing for
immune and inflammatory
effector mechanisms.